3Sm Challenge Model Protocol

NCT04753892 | Completed

• 1 other identifier: 21HH6540
• Study Type: interventional
• Target: 8
• Locations: 1 country
• Sites: 1

Brief Summary

The 3Sm challenge study is a small clinical study in eight healthy volunteers who will be injected with a protein which includes a short portion ('3Sm peptide') which is derived from a part (the '3S region') of the coat protein of HIV. The researchers believe that the 3Sm peptide might trigger an immune response which includes rare antibodies able to neutralise a wide range of different strains of HIV. The results will be useful in guiding the development of future vaccines against HIV, and other diseases.

Conditions

Healthy

Outcome Measures

Primary Outcomes (2)

• Serum titres of 3Sm antibodies

  ELISA read-outs

  From Month 0 to Month 6

• Frequency of 3Sm secreting B cells in peripheral blood

  ELISpot read-outs

  From Month 0 to Month 6

Study Arms (1)

Arm 1

EXPERIMENTAL

The 3Sm peptide is conjugated to a mutant diphtheria carrier protein (CRM197) and the resulting challenge agent (3SM2-G-CRM197) will be mixed with a squalene adjuvant before intramuscular administration at Months 0, 1, 2 and 4, at a dosage of 32 micrograms of 3SM2-G-CRM197 and 9.7 micrograms of adjuvant.

Other: 3SM2-G-CRM197 with squalene adjuvant

Interventions

3SM2-G-CRM197 with squalene adjuvant OTHER

Immune challenge agent

Arm 1

Eligibility Criteria

• Age: 18 Years - 55 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• Healthy male and female participants aged between 18 and 55 years on the day of screening.
• Willing and able to provide written informed consent.
• Available for all follow-up visits for the duration of the study.
• Entered into and obtained clearance from The Over volunteering Prevention System (TOPS) database (to avoid impact of any co-administered investigational products or treatments on our outcomes).
• If female and of childbearing potential, willing to use a highly effective method of contraception from screening until a minimum of 6 weeks after the last immunogen challenge. Periodic abstinence (calendar, symptothermal and post-ovulation methods) and withdrawal are not acceptable methods of contraception.
• If male and not sterilised, willing to avoid impregnating female partners through the use of condoms or sexual abstinence from screening until a minimum of 6 weeks after the last immunogen challenge, unless female partners are using a highly effective method during the same time period.
• Registered with a GP in the UK prior to enrolment into the study.
• Willing to grant authorised persons access to his/her trial-related medical record and GP records either directly or indirectly
• Willing to avoid all vaccines from within 4 weeks before the first immunogen challenge through to 4 weeks after the final challenge, with the exception of seasonal influenza vaccine which may be given more than 7 days before or after the experimental immunogen, and deployed COVID-19 vaccine which may be given 14 days before or after the experimental immunogen (and at least 28 days is encouraged). It is recommended that participants have an up to date vaccination status for any required immunisations.

You may not qualify if:

• Pregnant or lactating
• History of any physical, medical, psychological or other condition, clinically significant laboratory, vital sign or examination finding at screening, or use of any medications which, in the opinion of the investigators, would interfere with the study objectives or participant's safety. This includes where there is a history of active disease requiring a clinically significant recent or planned investigation or change in treatment, including cardiac, respiratory, endocrine, metabolic, autoimmune, liver, neurological, oncological, psychiatric, immunosuppresive/immunodeficient or other disorders. Individuals with mild/moderate, well-controlled co-morbidities, of those that are no longer deemed clinically active or clinically significant by the investigator are allowed.
• History of anaphylaxis or angioedema.
• History of severe or multiple allergies to drugs or pharmaceutical agents.
• History of severe local or general reaction to vaccination defined as:
• local: extensive, indurated redness and swelling involving most of the arm, not resolving within 72 hours
• general: fever ≥39.5 °C within 48 hours; bronchospasm; laryngeal oedema; collapse; convulsions or encephalopathy within 72 hours
• Previous receipt of an investigational vaccine or immunogen based on HIV envelope.
• Detection of antibodies to HIV.
• Detection of antibodies to Hepatitis C.
• Unable to read and/or speak English to a fluency level adequate for the full comprehension of study procedures and consent.
• Participation in another study, or treatment with an investigational drug within 28 days of screening, which in the opinion of the investigator would interfere with study objectives or compromise the participant's safety.

Sponsors & Collaborators

• Imperial College London: lead
• Minka Therapeutics: collaborator
• ANRS, Emerging Infectious Diseases: collaborator

Study Sites (1)

NIHR Imperial Clinical Research Facility

London, Please Select..., W12 0HS, United Kingdom

Location

Study Officials

• Katrina Pollock, MD

  Imperial College London

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NA
• Masking: NONE
• Purpose: BASIC SCIENCE
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: February 12, 2021
• First Posted: February 15, 2021
• Study Start: September 10, 2021
• Primary Completion: July 20, 2022
• Study Completion: July 20, 2022
• Last Updated: July 27, 2022

Record last verified: 2022-07

Data Sharing

• IPD Sharing: Will not share

Locations

GB (1)